EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis

Lin-Lu Li iD, Cheng-Feng Yu, Hong-Ting Xie, Zheng Chen, Bo-Hui Jia, Fei-Yu Xie, Ya-Fang Cai, Peng Xue, Shi-Jie Zhu

Cancer Medicine · 2023-05 · 12 (10) · 11211-11233

DOI: 10.1002/cam4.5800 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Medicine, online erschienen am 10.05.2023. Verfasst von Lin-Lu Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, 100102, Beijing, China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Neoplasms, Second Primary. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this meta‐analysis was to summarize the available results of immunotherapy predictors for small cell lung cancer (SCLC) and to provide evidence‐based information for their potential predictive value of efficacy.

Methods

We searched PubMed, EMBASE, Web of Science, The Cochrane Library, and ClinicalTrials (from January 1, 1975 to November 1, 2021). The hazard ratios (HR) and its 95% confidence intervals (CIs) and tumor response rate of the included studies were extracted.

Results

Eleven studies were eventually included and the pooled results showed that programmed cell death ligand 1 (PD‐L1) positive: objective response rate (ORR) (relative risk [RR] = 1.39, 95% CI [0.48, 4.03], p = 0.54), with high heterogeneity ( p = 0.05, I 2 = 56%); disease control rate [DCR] (RR = 1.31, 95% CI [0.04, 38.57], p = 0.88), with high heterogeneity ( p = 0.04, I 2 = 75%); overall survival (OS) (HR = 0.89, 95% CI [0.74, 1.07], p = 0.22); and progression‐free survival (PFS) (HR = 0.83, 95% CI [0.59, 1.16], p = 0.27), with high heterogeneity ( p = 0.005, I 2 = 73.1%). TMB‐High (TMB‐H): OS (HR = 0.86, 95% CI [0.74, 1.00], p = 0.05); PFS (HR = 0.71, 95% CI [0.6, 0.85], p < 0.001). Lactate dehydrogenase (LDH) >upper limit of normal (ULN): OS (HR = 0.95, 95% CI [0.81, 1.11], p = 0.511). Asian patients: OS (HR = 0.87, 95% CI [0.72, 1.04], p = 0.135); White/Non‐Asian patients: OS (HR = 0.83, 95% CI [0.76, 0.90], p < 0.001). Liver metastasis patients: OS (HR = 0.93, 95% CI [0.83, 1.05], p = 0.229); PFS (HR = 0.84, 95% CI [0.67, 1.06], p = 0.141). Central nervous system (CNS) metastasis patients: OS (HR = 0.91, 95% CI [0.71, 1.17], p = 0.474); PFS (HR = 1.03, 95% CI [0.66, 1.60], p = 0.903).

Conclusion

The available research results do not support the recommendation of PD‐L1 positive and TMB‐H as predictors for the application of immune checkpoint inhibitors (ICIs) in SCLC patients. LDH, baseline liver metastasis and CNS metastasis may be used as markers/influencing factors for predicting the efficacy of ICIs in SCLC patients. Non‐Asian SCLC patients had better efficacy with ICIs in our results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungLiver NeoplasmsNeoplasms, Second PrimaryLung NeoplasmsHumansImmune Checkpoint InhibitorsB7-H1 AntigenBiomarkersL-Lactate Dehydrogenase

Stichwörter der Autor:innen

biomarkersimmune checkpoint inhibitorsmeta-analysissmall cell lung cancer

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenBiomarkersL-Lactate Dehydrogenase

Autor:innen und Institutionen

  • Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, 100102, Beijing, China.
  • Graduate School, Beijing University of Chinese Medicine, 100029, Beijing, China.
  • Beijing Sihui West District Hospital, 100082, Beijing, China.

ORCID-Profile: Lin-Lu Li

Zitieren

APA

Li, L. L., Yu, C. F., Xie, H. T., Chen, Z., Jia, B. H., Xie, F. Y., Cai, Y. F., Xue, P., & Zhu, S. J. (2023). Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis. Cancer Medicine, 12(10), 11211-11233. https://doi.org/10.1002/cam4.5800

Vancouver

Li LL, Yu CF, Xie HT, Chen Z, Jia BH, Xie FY, et al. Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis. Cancer Medicine. 2023;12(10):11211-11233. doi:10.1002/cam4.5800

BibTeX
@article{Li2023,
  author = {Li, Lin-Lu and Yu, Cheng-Feng and Xie, Hong-Ting and Chen, Zheng and Jia, Bo-Hui and Xie, Fei-Yu and Cai, Ya-Fang and Xue, Peng and Zhu, Shi-Jie},
  title = {Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {10},
  pages = {11211--11233},
  doi = {10.1002/cam4.5800}
}
Kostenlos starten →